©2018 by SYNG Pharmaceuticals I Privacy Policy

Targeting “undruggable” proteins

Developing a simple blood test and first-in-class non-hormonal therapy for endometriosis

 

Endometriosis affects one in ten women

30-50% of women with endometriosis face infertility

Despite being one of the most prevalent female reproductive disorder characterized by debilitating menstrual pain, discomfort during intercourse, abnormal vaginal bleeding, chronic pelvic pain and infertility, the disease remains misdiagnosed, misunderstood and ineffectively treated. There is no rapid diagnostic for endometriosis. Current hormone-based therapies are partly ineffective and often have significant side effects.


SYNG Pharmaceuticals Inc. (SYNG Pharma) is an Ontario based biotech, developing a new first-in-class diagnostic test and therapeutic for endometriosis. 

Woman in Black
 

Our Technology

In vitro diagnostic and non-hormonal therapy for endometriosis

Pipetting Samples
 

Media & Press Updates

Being a Biotechnology Start-up we operate in a fast-paced world where changes happen often and quickly. This media section includes exciting news and updates about SYNG Pharmaceuticals, as well as industry news and analysis. If you have any questions about our articles, please get in touch today.

 

We always have a story to tell, so check our news section often and get in touch if you need more information!

Get in Touch

info {@} syngpharma.com

613-532-9426

No more Pain

We are getting ready with Endometriosis Test & Non-hormonal Therapy